Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lymphoma
FDA Oncology Update
,
Lymphoma
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
Read More
HOPA Abstracts
,
Clinical Trials
,
Leukemia
,
Lymphoma
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Read More
FDA Oncology Update
,
Lymphoma
Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients
Read More
Meeting Highlights
ASH Highlights
,
CAR T-Cell Therapy
,
Lymphoma
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
Read More
Meeting Highlights
ASH Highlights
,
Clinical Trials
,
Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Read More
FDA Oncology Update
,
Lymphoma
Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma
Read More
Meeting Highlights
ASH Highlights
,
CAR T-Cell Therapy
,
Lymphoma
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy
Read More
Meeting Highlights
ASH Highlights
,
Lymphoma
,
Novel Pharmaceuticals
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma
Read More
Meeting Highlights
ASH Highlights
,
Immunotherapy
,
Lymphoma
Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma
Read More
Leukemia
,
Lung Cancer
,
Lymphoma
,
FDA Oncology Update
November 25, 2019 – Oncology News & Updates
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 28